Zum Hauptinhalt springen
Dekorationsartikel gehören nicht zum Leistungsumfang.
Drugs for HER-2-positive Breast Cancer
Buch von Maria Sibilia (u. a.)
Sprache: Englisch

160,49 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Aktuell nicht verfügbar

Kategorien:
Beschreibung
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Zusammenfassung

Contemporary monograph on the treatment of breast cancer.-

Gives a comprehensive account of drugs for HER2-positive breast cancer.-

A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology

Includes supplementary material: [...]

Inhaltsverzeichnis

Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Details
Erscheinungsjahr: 2011
Fachbereich: Toxikologie
Genre: Medizin
Rubrik: Wissenschaften
Medium: Buch
Reihe: Milestones in Drug Therapy
Inhalt: x
110 S.
ISBN-13: 9783034600934
ISBN-10: 3034600933
Sprache: Englisch
Herstellernummer: 12548170
Ausstattung / Beilage: HC runder Rücken kaschiert
Einband: Gebunden
Redaktion: Sibilia, Maria
Grunt, Thomas W.
Bartsch, Rupert
Zielinski, Christoph C.
Herausgeber: Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al
Hersteller: Springer Basel
Springer Basel AG
Milestones in Drug Therapy
Maße: 241 x 160 x 13 mm
Von/Mit: Maria Sibilia (u. a.)
Erscheinungsdatum: 07.01.2011
Gewicht: 0,376 kg
Artikel-ID: 101383830
Zusammenfassung

Contemporary monograph on the treatment of breast cancer.-

Gives a comprehensive account of drugs for HER2-positive breast cancer.-

A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology

Includes supplementary material: [...]

Inhaltsverzeichnis

Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Details
Erscheinungsjahr: 2011
Fachbereich: Toxikologie
Genre: Medizin
Rubrik: Wissenschaften
Medium: Buch
Reihe: Milestones in Drug Therapy
Inhalt: x
110 S.
ISBN-13: 9783034600934
ISBN-10: 3034600933
Sprache: Englisch
Herstellernummer: 12548170
Ausstattung / Beilage: HC runder Rücken kaschiert
Einband: Gebunden
Redaktion: Sibilia, Maria
Grunt, Thomas W.
Bartsch, Rupert
Zielinski, Christoph C.
Herausgeber: Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al
Hersteller: Springer Basel
Springer Basel AG
Milestones in Drug Therapy
Maße: 241 x 160 x 13 mm
Von/Mit: Maria Sibilia (u. a.)
Erscheinungsdatum: 07.01.2011
Gewicht: 0,376 kg
Artikel-ID: 101383830
Warnhinweis